News
JNJ
164.10
+1.55%
2.50
Johnson & Johnson price target raised to $166 from $163 at Wells Fargo
TipRanks · 5h ago
Hold Rating for Johnson & Johnson Amid 2024 Growth Deceleration and 2025 Optimism
TipRanks · 6h ago
Hold Rating Maintained for Johnson & Johnson Amid Mixed Sector Performance and EPS Guidance Concerns
TipRanks · 6h ago
Johnson & Johnson: Balancing Growth Potential with Market Challenges and Legal Risks
TipRanks · 6h ago
Bridgeport jury determines J&J to pay $15M over talc-based powder
TipRanks · 7h ago
Johnson & Johnson: Strong Q3 Performance and Upward Sales Guidance Bolster Buy Rating
TipRanks · 10h ago
Cancer Drugs Propel J&J Beyond Wall Street Estimates
Benzinga · 11h ago
Trending: Johnson & Johnson Posts Higher-Than-Expected Sales
Dow Jones · 11h ago
Johnson & Johnson: Strong Performance Yet Fairly Priced, Leading to Hold Rating
TipRanks · 12h ago
Johnson & Johnson price target raised to $170 from $160 at Stifel
TipRanks · 12h ago
Legend Biotech weakness a buying opportunity, says Barclays
TipRanks · 12h ago
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
The Motley Fool · 12h ago
Wall Street Lunch: Chip Stocks Slide On ASML Early Numbers
Seeking Alpha · 12h ago
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
Benzinga · 12h ago
Chipmaker Stocks Sink On ASML Earnings Leak, Oil Eyes Worst 1-Day Drop This Year, Small Caps Rally: What's Driving Markets Tuesday?
Benzinga · 13h ago
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
Seeking Alpha · 13h ago
JNJ releases positive data on nipocalimab for myasthenia gravis in adolescents
Seeking Alpha · 13h ago
Daily Dividend Report: WHR,NNN,JNJ,IP,ACI
NASDAQ · 14h ago
Google Goes Nuclear For AI Power, Israeli Restraint Impacts Stocks, Gold, And Oil
Benzinga · 14h ago
Big banks, UnitedHealth report quarterly earnings: Morning Buzz
TipRanks · 14h ago
More
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).